Market Information
Middle East and North Africa

The Biomedical Market
in Israel

August 2000

Prepared by the Market Research Centre and the Canadian Trade Commissioner Service

© Department of Foreign Affairs and International Trade
(FaxLink no. 42567)

Report prepared by the Market Research Centre
Market Support Division (TCM)
Department of Foreign Affairs and International Trade
125 Sussex Drive, Ottawa K1A 0G2
Fax: (613) 943-1103
E-mail: mrc@dfait-maeci.gc.ca

The Market Research Centre produces a wide range of market reports by region and sector for Canadian exporters. These reports are available from:
- the FaxLink Domestic service (613-944-4500); and
- DFAIT's InfoExport Internet site (http://www.infoexport.gc.ca).

The Government of Canada has prepared this report based on primary and secondary sources of information. Readers should take note that the Government of Canada does not guarantee the accuracy of any of the information contained in this report, nor does it necessarily endorse the organizations listed herein. Readers should independently verify the accuracy and reliability of the information.

EXECUTIVE SUMMARY

There were 135 biotechnology companies in Israel in 1999 with a total of $600 million¹ in sales, 3800 employees and exports estimated at $550 million. The biotechnology market is expected to be valued at $1.2 billion in 2000 and $2.6 billion by 2003. Analysts predict that by 2003, as many as 200-250 companies will be working in this sector and that investments will grow to $1.4 billion. Pharmaceutical and diagnostics firms represent 72% of the Israeli biotechnology industry. 

Israel has one of the world's most skilled and educated work forces, with more doctors, scientists and engineers per capita than any other nation. The reputation of Israel's work force, as well as lower costs for conducting clinical trials and a history of bringing new products to an advanced stage of development more rapidly than anywhere else in the world, makes Israel an attractive place for foreign companies to conduct clinical trials or establish research partnerships.

There is strong government support for the biotechnology industry within Israel through programs to match research funding, establish technology incubators, and encourage bi-national co-operation. However, despite a rapidly expanding medical and pharmaceutical industry, the Israeli market is still quite immature and dependent on imported goods. In order to reduce the costs of medication and encourage more competition in the market, the Health and Justice ministers signed regulations to allow parallel imports of pharmaceuticals in May 2000. Despite continued opposition from international pharmaceutical companies, the regulations will take effect on September 1, 2000.

Characterized by a high level of competition, Israel is expected to become a centre for the development of pharmaceuticals, especially generic brands. Best prospects for growth in the industry are in bio-electronics, pharmacogenomics, proteomics, bioinformatics and structure based drug design. Pure biotechnology drug discovery requires greater investment and a longer development time, postponing marked growth in this sector until the Israeli market matures.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

MARKET OVERVIEW

Key Factors Shaping Market Growth
Opportunities

COMPETITIVE ENVIRONMENT

Local Capabilities
International Competition
Canadian Position
Competitive Advantage through Canadian Government Policies and Initiatives

PRIVATE-SECTOR CUSTOMERS

PUBLIC-SECTOR CUSTOMERS

Government Organizations
Government Procurement Regulations

MARKET LOGISTICS

Suggested Business Practices
Intellectual Property Protection
Import Regulations
Export Credit Risks, Restrictions on Letters of Credit, Currency Controls

APPENDIX A: COMPANY INFORMATION

PROMOTIONAL EVENTS

KEY CONTACTS AND SUPPORT SERVICES

BIBLIOGRAPHY

OTHER REFERENCE MATERIALS

Useful Internet Sites

MARKET OVERVIEW

Israel is a modern and diverse country of over 6 million people, located on a narrow strip of land along the east shore of the Mediterranean Sea. With the third-highest growth domestic product (GDP) per capita in the developing world (after Hong Kong and Singapore), Israel ranks as one of the most competitive nations of the 21st century. While the small size of the Israeli economy has limited the country's capital resource base, the expertise of the work force has proven to be it's most important commodity.

Home to one of the world's most skilled and educated work forces (the majority of whom speak English), Israel has more scientists and engineers per capita than any other nation and approximately 4.5 physicians to every 1000 people. Israel boasts leading researchers in life sciences, computer technology and engineering who produce a noteworthy 1% of the world's scientific publications. In the life sciences field, there are seven universities, five technical colleges and ten specialized research institutes engaged in advanced biotechnological research. An estimated 35% of all academic scientists in Israel work in the life sciences field and spend 40-50% of all academic research funding.

By 1997, the biotechnology industry had commercialized 19 products, with 32 in clinical trails awaiting approval, and 50 more at the research and development phase. There were 135 biotechnology companies in Israel in 1999 (an increase from only 25 companies in 1988), with sales of $600 million and exports estimated at $550 million. Sales of biotechnology products are expected to top $1.2 billion in 2000 and are forecasted to reach $2.6 billion by 2003. There were 3800 people employed in the biotechnology sector in 1998, an 8% increase from the previous year. Analysts predict as many as 200-250 companies working in this sector by 2003, with investments growing to $1.4 billion in the same period. Pharmaceutical and diagnostics firms represent 72% of the Israeli biotechnology industry; agricultural biotechnology accounts for 20%; and the remainder includes veterinary and environmental applications.

Biopharmaceuticals are the most significant sector of the Israeli biotechnology market. However, the distinction between traditional pharmaceutical firms and those employing biotechnology in the development of medical products is difficult to establish. As the science behind biotechnology develops, many traditional pharmaceutical companies are turning their attention to the potential of biotechnology in both product development and manufacturing technologies.

The estimated domestic value of the pharmaceutical market in Israel in 1998 was $1.1 billion, growing at an average rate of about 10% annually. Sales by domestic manufacturers totalled $1.35 billion in 1998; 50% of total sales were exported. In spite of a rapidly expanding medical industry, the Israeli market is still quite dependent on imported goods. Imported pharmaceuticals were approximately 40% of the total market in 1998, or $720 million. Imports primarily originate from the United States, Switzerland, France, Germany, Ireland and the United Kingdom, with Canadian imports having a marginal share at about 1% in recent years. Currently, the vast majority of Israel's pharmaceutical exports are to the United States and the European Union, particularly the United Kingdom, Italy and the Netherlands. Total exports are forecast to rise to $1.1 billion by 2000 and to more than double to $2.3 billion by 2003.

In 1996, the over-the-counter (OTC) drug market represented 12% of Israel's total national drug market, compared with 20% in the United States and 28% in both France and Germany. Annual OTC consumption in Israel averages $12 per capita, well below average for most westernized countries. The OTC market is predicted to be one of the most promising growth sectors in coming years. There is strong government support for the biotechnology industry within Israel through programs to match research funding, establish technology incubators, and encourage bi-national co-operation (see the Key Contacts section for a complete listing of biotechnology incubators). The Office of the Chief Scientist of the Ministry of Industry and Trade as well as the Ministry of Science and Technology are responsible for biotechnology development and seek to promote improvement of academic and industrial relations to improve commercialization of basic research². The Ministry of Industry and Trade sponsors training projects, or industrial incubators, which partner new immigrants to Israel who have backgrounds in science and technology with experienced Israeli entrepreneurs. The mentor's role is to assist with the process of moving promising ideas through research and to commercialization. The program has been very successful, particularly with Russian immigrants who have the technical experience in life sciences, but had not previously been encouraged to pursue individual initiative.

The National Biotechnology Steering Committee, established in 1987, advises the Israeli government on the development of biotechnology, encourages research and entrepreneurial activities, and promotes international co-operation. Government support also extends beyond research and development to include grants and incentives for start-up costs, marketing and infrastructure development. The MAGNET program, administered by the Ministry of Industry and Trade, encourages development of innovative generic technologies through collaborations between industry and the scientific community. MAGNET will underwrite up to 65% of a project's budget. In 1998, four biotechnology projects received funding under this program. In 1999, the program received a budget allotment of $300 million over five years. MAGNET also established a bioinformatics consortium called Da'at to encourage collaboration among 7 companies and 2 academic institutes. Da'at received funding of $16 million over 5 years.

In order to bridge the gap between basic research and commercialization, the Government has established "national open centres". The centres work on intermediate strategic research is areas such as protein purification and micro sequencing, genomic technologies and gene therapy, and high-throughput screening technologies. Projects put through these centres are chosen by a panel that bases its decisions on scientific excellence and future applications.

Canadian companies interested in fostering research and development relationships with Israeli companies are also encouraged to consult the MATIMOP program. MATIMOP is a public non-profit organization that promotes joint industrial development of advanced technologies. The program's Web site contains a database outlining co-operative program opportunities that span a range of advanced technologies.

Key Factors Shaping Market Growth

In spite of having the scientific know-how and personnel, the Israeli biotechnology industry has yet to achieve the level of maturity and development of its competitors, particularly the United States, Canada, Germany and the United Kingdom. While there has been some progress over the past decade with strong government support and the emergence of several large- and medium-sized firms with sufficient infrastructure to develop and test of drugs, further expansion of the infrastructure is needed, as well as the development of entrepreneurial ability in management. The Israeli Biotechnology Organization is currently working in co-operation with the Israel Manufacturers' Association in implementing a fast-track management program aimed at matching successful executives with Israeli start-up companies.

Other developments to encourage growth in the biotechnology industry in Israel include the Clal Biotech Fund. Led by Clal Biotechnology, a group of investors established a $150-million consortium to invest in biotechnology companies in 1998. The group invested $22 million in Compugen and $3.8 million in Neuro Survival Technologies. The Clal Biotech Fund is currently examining three investments in foreign companies in the US and Europe. In addition to the Clal Biotech Fund, Koor Group and the Israel Corporation (among Israel's largest holding companies) have jointly established a $44 million fund dedicated to biotechnology investments.

The Ministry of Science, in cooperation with the Weizmann Institute of Science, established the Israel National Node (INN) for bioinformatics training and support in 2000. The institute is part of the government's effort to strengthen R&D and manufacturing infrastructures by encouraging closer collaboration between academia and industry.

Israel has a strong reputation for a highly skilled work force, lower costs for conducting clinical trials as well as a history of bringing new products to an advanced stage of development more rapidly than anywhere else in the world. Israel also has a highly diverse population as a result of years of immigration, providing researchers a heterogenous population for clinical trial research. Israel also has a well-developed medical infrastructure, universal health insurance system and considerable number of physicians. Companies from the United States and the European Union are increasingly interested in the research and development environment in Israel, further encouraging growth in the industry.

There are hundreds of biotechnology projects currently being developed in Israel, most of which receive government funding. A notable change in emphasis in recent years has been a move away from development of diagnostics and agricultural products to research on new pharmaceuticals. Areas where major advances have been made include the use of molecular modeling to design new and improved drugs, synthetic polyamino acids for drug development, drug delivery techniques and drug design by peptide modification.

In 1998, Israel announced reformed drug import regulations that included major changes in pricing, importing and approvals for new drugs. As described in more detail below, medications approved by the U.S. Food and Drug Administration (FDA) or the European Medical Regulations Agency will be approved by the Ministry of Health in Israel much quicker than those that have not received approval.

Further changes, as of February 1999, included allowing parallel drug imports. In the past, any company registering an imported pharmaceutical with the Ministry of Health had a monopoly on the drug, whereby drugs were imported only by representatives with exclusive agreements with the manufacturer. In response to proposed changes to allow parallel imports, 15 representatives of international pharmaceutical companies established a non-profit lobbying organization called Pharma Israel to oppose the measure. The association members argued that medications supplied by the manufacturer ensure the quality of handling, packaging, storage and transportation.

They also argued that parallel imports may threaten intellectual property rights. The Government argued in return that parallel imports would increase competition in the industry and could reduce the costs of some medications in Israel. On May 30, 2000, the ministers of Health and of Justice signed regulations allowing parallel imports. The regulations were signed after Clalit Health Services filed a lawsuit and the High Court of Justice responded by demanding an explanation for the delay. Despite continued opposition from international pharmaceutical companies, the regulations will take effect on September 1, 2000.

The United States and Germany are Israel's most active scientific collaborators with programs including the Bi-National U.S.-Israel Science Foundation (BSF) and the Germany-Israel Foundation (GIF). Israel receives the third-largest amount of grant funding from the U.S. National Institutes of Health outside the United States.

Opportunities

While there is a need for strategic alliance opportunities for small or medium-sized companies, the Israeli National Biotechnology Committee has predicted that new ventures and partnerships will result in sales of $1.1 billion in 2000 and reach $2.6 billion in 2003 - or six times more than 1997 sales. Israel has a multilingual, immigrant population with cultural, historic and business ties to almost every other nation. In recent years, over 700 000 immigrants have been absorbed from Russia, 67% of which were previously employed in professional, scientific, engineering or technical positions in the former Soviet Union. This highly trained scientific elite offers significant growth opportunities in the industry and opportunities for Canadian firms to partner with small and medium-sized Israeli enterprises. Israeli partners can help Canadian firms with technical expertise and commitment to ongoing research and development to enter the market, through strategic alliances and technology transfer agreements.

Best prospects for growth in the industry are in bio-electronics, bio-informatics, pharmacogenomics, proteomics, and structure based drug design. Pure biotechnology drug discovery requires greater investment and a longer development time, postponing marked growth in this sector until the Israeli market matures. Currently, Israeli biotechnology firms tend to sell their technology to international investors or multinational concerns, rather than take the risk to develop the product further.

COMPETITIVE ENVIRONMENT

Local Capabilities

In spite of recent growth, the Israeli pharmaceutical market remains relatively small. The two main producers and importers, Teva Pharmaceutical Industries and Agis Industries, have a combined market share of 50-60%. These and other companies, including Biotechnology General (BTG), Hazera, Interpharm (IPL), Orgenics, and Pharmos, have begun to build critical infrastructure for drug development and testing. The close co-operation between the manufacturing sector and research institutes, universities and medical centres has resulted in a particularly efficient development of new products from the initial research phase through to manufacturing and marketing. Characterized by a high level of competition, Israel is expected to become a centre for the development of pharmaceuticals, especially generic brands. Teva has been particularly successful in the generic drug market.

International Competition

By far, the largest biotechnology industry in the world is the United States, with Germany, the United Kingdom, France and Canada following. More than 90% of advanced biotechnology products on the world market are health related and it is expected that about three quarters of the total world demand for biotechnology will continue to be in the health sector. World sales of biopharmaceuticals have grown more than seven-fold over the past decade and should exceed $26 billion by 2003. The biopharmaceutical portion of world prescription drug sales is expected to triple from 5% to 15% by 2005.

Canadian Position

The Canadian biotechnology industry has flourished over the last several years. With almost 500 companies, collective revenues of more than $1.9 billion and research expenditures of more than $1.5 billion, Canada is poised to become a world leader in pharmaceutical research and production. Canadian pharmaceutical exports to Israel were estimated to be close to 1% of the market in 1997.

Fostering growth in the Canadian biotechnology sector is consistent investment in research and development, financial support by private and public agencies, a solid regulatory framework, strong human resources, and public acceptance of biotechnology-derived products. In 1999, the Canadian government announced a $550-million increase in health research funding over three years and reinforced biotechnology as an important growth sector for the future. The funding announcement included the creation of the Canadian Institutes of Health Research, $200 million in additional funding for the Canadian Foundation for Innovation, and $150 million in additional funding for Technology Partnerships Canada. This commitment to biotechnology was strengthened in the federal budget in February 2000 with the announcement of $160 million to fund five genomic science centres across Canada, $900 million for university and hospital research infrastructure and $900 million for additional research chairs at Canadian universities. The government also allocated $90 million to strengthen Canada's regulatory capacity in the area of biotechnology.

Canada's positive relations with the world's most prominent economies, as well as its global reputation for scientific excellence, give Canadian companies an advantage in expanding their businesses to overseas markets. Canadian firms are well positioned to provide joint-venture partnerships and commercialization expertise, as well as a broad range of products resulting from Canadian research and development efforts. Biovail of Mississauga, Ontario has recently signed an agreement with Teva Pharmaceutical Industries, Israel's largest pharmaceutical company, to develop and market a line of delayed-release drugs produced by Biovail.

In December 1999, Teva signed a letter of intent to acquire Novopharm of Canada from Dan Family Holdings. The value of the deal is approximately $385 million. The acquisition did not include Novopharm Biotech and was finalized in June 2000. 

Competitive Advantage through Canadian Government Policies and Initiatives

Canada-Israel Free Trade Agreement

The Canada-Israel Free Trade Agreement (CIFTA) was implemented on January 1, 1997, giving each country duty-free access to each other's market for most products, and levelling the playing field between Canadian exporters and their competitors in the Israeli market from the United States, the European Union, Turkey and Eastern Europe. Increased access has enhanced the competitiveness of Canadian suppliers to this market.

Canada-Israel Industrial Research and Development Foundation

Established in 1994, the Canada-Israel Industrial Research and Development Foundation (CIIRDF) provides companies in either country with an introductory service for the purpose of creating R&D alliances. The program contributes half of the costs of joint R&D projects (up to $50,000 over one year for approved pilot projects and up to $750,000 over three years to fund approved full-scale projects) for eligible Canadian or Israeli firms operated and headquartered in either Canada or Israel. At least 30% of the cash costs on any individual project must be spent in either Canada or Israel, contributions are repayable from commercial revenues from the project. For more information, contact the Canada-Israel Industrial Research and Development Foundation.

Export Development Corporation

Export Development Corporation (EDC) offers export financing and insurance to Canadian exporters. Additionally, insurance can be provided for larger transactions that are subject to the terms and conditions established by the buyer. EDC prefers to work through letters of credit, bank credits or bank guarantees. Approval for financing is considered on a case-by-case basis.

Canadian Commercial Corporation

The Canadian Commercial Corporation (CCC) gives Canadian companies access to financing and better payment terms under the Progress Payment Program (PPP). The PPP concept was developed as a partnership between major Canadian financial institutions and the CCC. It enables the exporter's bank to open a project line of credit for the exporter's benefit, based on CCC approval of the project and the exporter's ability to perform. The CCC will also act as a prime contractor on behalf of Canadian small and medium-sized enterprises, giving those businesses increased credibility and competitive advantage.

Program for Export Market Development

The Program for Export Market Development (PEMD) helps Canadian companies enter new markets by sharing the costs of activities that companies normally could not or would not undertake alone, thereby reducing risks involved in entering a foreign market. Eligible costs and activities include market visits, trade fairs, incoming buyers, product testing for market certification, legal fees for international marketing agreements, transportation costs of offshore company trainees, product demonstration costs, promotional materials, and other costs necessary to execute a market development plan. Activity costs are shared on a pre-approved, 50/50 basis.

The PEMD refundable contribution ranges from $5,000 to a maximum of $50,000. Preference is given to companies with fewer than 100 employees for a firm in the manufacturing sector and 50 in the service industry, or with annual sales between $250,000 and $10 million. Other components of the program include international bid preparation (Capital Project Bidding) and, for trade associations, developing international marketing activities for their membership. For additional information visit http://www.infoexport.gc.ca/pemd-e.asp or call 1-888-811-1119.

WIN Exports

WIN Exports, a database of Canadian exporters and their capabilities, is used by trade commissioners around the world and by Team Canada Inc partners in Canada to match Canadian suppliers with foreign business leads, and to share information on trade events. To register your company in WIN Exports or for more information, visit http://www.infoexport.gc.ca/winexports/menu-e.asp or call 1-888-811-1119.

Technology Partnerships Canada

Industry Canada's Technology Partnerships Canada is an investment loan fund of $250 million that was created to assist the development and eventual export of hightechnology products. Investment loans must be fully repaid and are intended to help ensure that products with high potential actually reach the market. Sectors within bioindustries supported by the program include: therapeutics, including clinical trials in phases I and II; diagnostics, including clinical trials in phases I and II; agri-food; aquaculture; and bio-remediation. For further information, contact Technology Partnerships Canada at 1-800-266-7531 or consult the Internet at http://tpc.ic.gc.ca.

PRIVATE-SECTOR CUSTOMERS

Israel's 630 privately owned pharmacies represent the second largest group of customers for for pharmaceutical products (the publically funded health-care system is the primary customer). The two largest drug store chains are SuperPharm and NewPharm.

PUBLIC-SECTOR CUSTOMERS

An advanced health-care system exists in both the private and public sectors in Israel, with total health expenditures estimated at about 8% of the GDP (or $12.4 billion in 1997). The public sector consumes 90% of imported and locally produced pharmaceuticals.

Since 1995, health insurance is guaranteed to all Israeli citizens. All residents are required to register with one of the health care organizations, which provide a standard and extensively subsidized selection of health services and drugs through one of four public "sick funds". In January 2000, a total of 96 drugs and 22 medical procedures were added to the list for reimbursement and are expected to cost the Israeli government an additional $60 million per year.

The largest of the sick funds is Kupat Holim of the Histadrut (General Sick Fund of the Labour Union), which insures about 65% of the total insured (or about 3.5 million people) and operates about 1200 clinics in Israel. It is the largest purchaser of drugs in Israel through a centralized purchasing scheme and a chain of in-house pharmacies.

The products sold through sick fund pharmacies have traditionally been the lowest prices in the market. Following in size are the Maccabi (19.6%), the Leumit (9.2%) and the Meuhedet (9.1%) funds, each offering various services through regional clinics, hospitals and specialized health institutions.

Source: Espicom Business Intelligence. Comparative Data, July 1999.

Government Organizations

The Ministry of Health is responsible for Israel's overall health policy and for providing direct services to the public through the operation of autonomous heath-care units. Israeli government departments, and government-owned companies and organizations are required to procure through tenders - the most effective way of gaining sales through this channel is through a local representative or agent. While open tenders are published in the local press, government-owned companies often use selective bidding practices whereby only selected companies are invited to bid on the contract. Participation at annual trade fairs can help to develop company and product exposure to this market segment.

Government Procurement Regulations

Under the Public Procurement Law and Regulations enacted in 1993, governmentowned companies and entities are required to procure by tender. "Industrial Cooperation" regulations contain an offset clause for tenders over $735,000 (US$500,000) for the purchase of local products or use of local content for at least 35% of the cost of the contract. Procurement is administered by the Ministry of Industry and Trade. Although Israel is a signatory to the World Trade Organization (WTO) Government Procurement Code, the "Buy Israel" regulation awards a 15% advantage to local companies. As well, the National Priority Zones Regulations award an additional 5-15% advantage to companies located in the national priority areas.

MARKET LOGISTICS

Tel Aviv is Israel's commercial and financial centre. Centrally located on the Mediterranean coast and having 25% of the population, it is where most companies are headquartered. The two major seaports are Haifa in the north and Ashdod in the south, each having good transportation links to the rest of the country.

Channels of Distribution

Good representation is the key to the Israeli market. Prospective exporters are recommended to use the services of a local representative/distributor or local agent who has a thorough knowledge of the market and well connected with key players. Governed by the Agencies Act of 1965, general common law principles of agency law apply to the termination or cancellation of agency agreements. An agreement for representation should specify the duration of the contract, provisions for exclusivity, compensation, promotional input and dispute settlement mechanisms. Exporters new to the Israeli market are advised to appoint a local agent with an understanding of the local market; contacts with the Ministry of Health, the sick funds and other major players; and the ability to promote products effectively.

An importer of pharmaceutical products must have a licence and be a resident of Israel, or a representative of a corporation registered in Israel. As a result, Canadian companies must either establish an office in Israel, or hire a distributor for their products. For assistance locating an agent or distributor, contact the Canadian Embassy in Israel.

Suggested Business Practices

The two official languages of Israel are Hebrew and Arabic, but English is widely spoken as the language of business and the one preferred for promotional materials. Most signs in public places are in all three languages. Yiddish, Russian, French and German are prominent among the languages used by immigrant groups. The business environment is westernized but likely to be less formal in both dress (especially during the summer months), and the use of first names without titles. Increasingly, businesses are moving toward a five-day working week, from Sunday until Thursday. Common office hours are from 8:00 a.m. until 4:00 p.m. Sunday to Thursday and from 8:00 a.m. until 1:00 p.m. on Friday.

Israel has no formal constitution. It has a modern, independent legal system based on a number of Basic Laws covering key areas of public life - such as the electoral system, the Knesset (parliament) and the legal system - as well as British case law, which effectively enforces property and contractual rights. Moreover, Israeli civil procedures provide that judgments from foreign courts may be accepted and enforced by local courts.

The financial sector is modern and efficient with a full range of financial institutions and instruments. There are few restrictions on foreign investment and investors and the regulatory environment and tax system favour foreign companies and investors. The Consular Affairs Bureau of the Department of Foreign Affairs and International Trade (DFAIT) provides country-specific travel information reports and advisories. Contact DFAIT (1-800-267-6788) or visit http://www.dfait-maeci.gc.ca/travelreport/menu_e.htm for more information. Canadians travelling in Israel should pay particular attention to their security and follow news reports carefully, as the security situation could change very rapidly.

Intellectual Property Protection

Israel is a member of the World Intellectual Property Organization, the Patent Cooperation Treaty, the Paris Convention for the Protection of Industrial Property, the Universal Copyright Convention and the Berne Copyright Convention. As a member of the WTO, Israel is currently revising its laws to bring them into compliance with the Trade Related Aspects of Intellectual Property Rights (TRIP) Agreement.

Patents

Israeli patent laws protects both the process and the product and is granted for 20 years from the date of the application, subject to payment of renewal fees. The owner of a patent must provide a local address when applying for a patent and the title must appear in both Hebrew and English (specifications, however, may be in either English or Hebrew). The "first to file" principal applies, whereby the first or prior use of a patent does not protect the owner from infringement by someone else who applies first for a patent in Israel. The use of the services of a patent attorney are recommended.

Generic Drugs

Through 1998 and 1999, Israel amended its patent laws to permit domestic manufacturers of generic drugs to develop generic versions of patented drugs prior to the expiration of the 20-year patent protection for the innovator. While the laws restrict production for use in research and for filing applications to regulatory authorities, it has no effective safeguards to restrict commercial exports.

The Israeli pharmaceutical market previously relied on licensed technology from foreign companies, or had to license their technology to large-scale manufacturers. Israeli generic drug manufacturers have now become large enough to undertake the commercial development of pharmaceuticals. These companies are opposed to any delay in research and development until after the full period of patent protection has expired.

The revised Israeli patent laws allow Israeli generic alternatives to be marketed as soon as the patent expires, when Israel's competitors would only be starting development of alternatives. This gives Israeli companies a jump start on generic drug competitors, and would likely result in Israeli generic manufacturers gaining a larger portion of the market.

Fearing the erosion of their competitive advantage, the United States and the European Union oppose Israel's revised patent laws and are currently considering taking the matter to the WTO under the TRIP Agreement. Furthermore, the European Union and the United States do not allow imports of generics while the patented drug is still protected and have threatened sanctions against Israel over Israel's interpretation of the TRIP Agreement. This objection, however, will not prevent other nations from purchasing Israeli exports. Canadian exporters are advised to follow this issue closely and take all necessary precautions to protect intellectual property.

Trademarks

Applications for trademark protection may be made by the owner or their agent with written authorization from the owner. All applicants must present a local address and pay the required fee of approximately $175. The term of protection for a trademark is seven years but is renewable indefinitely for periods of 14 years upon payment of required fees. Priority of registration is given to the first local user of the trademark and every application must specify goods or services falling within one class only. Under the terms of the Paris Convention, where an application to register a trade or service mark in another signatory country has been made, the applicant has a right to claim priority for registration of the same trademark in Israel for the same use.

Import Regulations

Free trade agreements have been signed with the European Union (1975), the United States (1985), the European Free Trade Alliance (1992) and Canada (1997). Under these agreements, there are no custom duties on pharmaceutical imports. Israel pursues a liberal import policy under which tariffs on products from most third-party countries were lowered to between 8% and 12% by 1998.

Most imports are free of licensing and quantitative restrictions. All imports are subject to a 15% c.i.f. (cost/insurance/freight) value port fee, as well as a value-added tax (VAT) of 17%. The VAT is recovered by the importer upon the resale of the goods and ultimately paid by the consumer in the final retail price.

The Ministry of Health imposes strict controls on the importation of pharmaceuticals. Medical drugs and substances for their preparation may be imported only through a licence holder who is either an Israeli resident or a representative of a company registered in Israel. To obtain a licence, a Registration of Medicinal Products must be submitted to the Ministry of Health. As of 1998, there has been a concerted effort to speed up the approval process for drugs imported from the United States, Canada, the European Union, Japan and Australia. Accordingly, drugs approved by the United States Food and Drug Administration (FDA) and/or the European Medical Regulation Agency will be licensed by the Ministry within two months, rather than the usual 4-month period.

Regulations regarding the pricing of imported drugs were introduced in 1998 by the Minister of Health. The previous regulations saw the importer use the price in the country of origin as a basis for the price in Israel. Officials argued that this policy created artificially high prices by encouraging importers to purchase drugs from expensive sources. The new regulation calls for prices to be set based on the lowestaverage price in Belgium, France, Germany and the United Kingdom.

Local Standards, Certificates or Registrations

All imports into Israel must have a label indicating the country of origin, the name and address of the producer and the Israeli importer, the content, weight and volume. In all instances Hebrew must be used. English may be added provided the print is no larger than the Hebrew print.

In addition, specific labelling regulations may apply to various types of pharmaceuticals. Exporters are advised to consult with the Israeli authorities or their local agent/importer to obtain specific requirements.

Export Credit Risks, Restrictions on Letters of Credit, Currency Controls

The most common method of payment is through a letter of credit that guarantees payment. Israeli importers prefer Cash Against Documents (CAD) and to collect an advance payment or an irrevocable bank guarantee on a portion of the shipment, given that there is no guarantee of payment with the CAD method. The most common terms are 30, 60 and 90 days.

APPENDIX A: COMPANY INFORMATION

• Interpharm Laboratories (a subsidiary of the Swiss company Ares Sereno), located in Nes Ziona, is the oldest biotechnology company in Israel. The company developed and manufactures Recombinant Interferon-Beta (Rebif) and other cytokines. Rebif is registered in the European Union for treatment of Multiple Sclerosis.
• Pharmos has received FDA approval in the United States for two of its ophthalmic products (Lotamax and Alrex) and is in phase II trials for a head trauma treatment.
• Bio-Technology General, based in Rehovot, markets a human growth hormone for treatment of severe muscle wasting in AIDS patients in both the European Union and the United States. The company also manufactures high-grade hyaluronic acid for use in cataract operations.
• Teva has received approval for Copaxone, a treatment for Multiple Sclerosis. The company has other products in development for the treatment of diabetes, various forms of cancer, epilepsy, lung and liver fibrosis and Alzheimer's disease.
  • Teva and H. Lundeck AS, a Dutch company, announced in November 1999 a strategic alliance for the development and marketing of two treatments for Parkinson's disease.
  • Teva also entered into a strategic alliance with Bio-Technology General in October 1999 to develop and sell generic recombinant therapeutic products. Bio-Technology General will focus on research and manufacturing and Teva will focus on marketing. The alliance is valued at approximately $30 million.
  • The U.S. division of Teva Pharmaceuticals announced plans in September 1999 to acquire Copley Pharmaceutical Inc., based in Canton, Massachuset. The transaction is valued at $323 million.
• Orgenics, a diagnostics firm, has developed a saliva test for AIDS to reduce danger to nurses exposed to blood products. The company also markets diagnostic kits for hepatitis, chlamydia, and H. Pylori.
• Health Care Technologies has developed in vitro diagnostics for AIDS, hepatitis, and chlamydia.
• In January 2000, Rehovot-based Clal Biotechnology announced it was in advanced stages of negotiation with an unnamed European pharmaceutical company for a $150-million investment. The European company plans to invest the money in exchange for rights to approved products.
• XTL Biopharmaceuticals Ltd, based in Rehovot, has concluded an agreement in December 1999 with Hoffmann - La Roche Ltd., to use XTL's TrimeraXTL transgenic mouse model for in vivo testing of candidate therapeutics for the treatment of hepatitis C infection.
  • XTL established U.S. operations in Ipswich, New Hampshire in January 2000.
  • XTL announced in April 2000 plans to raise $60-70 million through an initial public offering on the London Stock Exchange sometime in 2000. This will be the first Israeli biotechnology company to list shares of the London exchange.

PROMOTIONAL EVENTS

Medax 2001
March 20-22, 2001
Tel Aviv Fairgrounds
Tel Aviv, Israel
Note: This show is held every two years and is attended by about 1500 exhibitors and more than 18 000 visitors from all over the world, in the medical and scientific professions.

Organizer:
Stier Group Ltd.
12 Tverski St.
Tel Aviv 67210, Israel
Tel.: (972-3) 562-6090
Fax: (972-3) 561-5463
E-mail: expo@stier.co.il
Internet: http://www.stier.co.il

Analiza
January 23-25, 2001
Tel Aviv Fairgrounds
Tel Aviv, Israel
Note: International laboratory equipment exhibition and Trade Fair

Organizer:
Stier Group Ltd.
12 Tverski St.
Tel Aviv 67210, Israel
Tel.: (972-3) 562-6090
Fax: (972-3) 561-5463
E-mail: expo@stier.co.il
Internet: http://www.stier.co.il

Bio2001
June 24-28, 2001
San Diego Convention Center
San Diego, CA

Organizer:
Biotechnology Industry Organization
1625 K Street NW, Suite 1100
Washington, DC 20006
Tel.: (202) 857-0237
Fax: (202) 857-0244
Internet: http://www.bio.org

BioEurope 2000
November 13-15, 2000
Hyatt Regency Hotel
Berlin, Germany

Organizer:
E.B.D. Group, Inc.
6120 Paseo Del Norte, Suite J-2
Carlsbad, CA 92009
Tel.: (760) 930-0500
Fax: (760) 930-0520
E-mail: Bioeurope2000@ebdgroup.com
Internet: http://www.ebdgroup.com/bio2000

KEY CONTACTS AND SUPPORT SERVICES

Canadian Government Contacts

Canadian Embassy in Tel Aviv
3 Nirim Street
Tel Aviv, Israel 67060
Tel.: (972-3) 636-3351
Fax: (972-3) 636-3385
Contact: Atalia Kahan
E-mail: atalia.kahan@dfait-maeci.gc.ca
Internet: http://www.infoexport.gc.ca

Department of Foreign Affairs and International Trade
125 Sussex Dr.
Ottawa, ON K1A 0G2
Market Support Division (TCM)
Tel.: (613) 996-1431
Fax: (613) 943-8820
Contact: Patricia Filteau, Trade Commissioner
E-mail: patricia.filteau@dfait-maeci.gc.ca
Internet: http://www.dfait-maeci.gc.ca
Middle East Division (GMR)
Tel.: (613) 944-6994
Fax: (613) 944-7975
Contact: Elaine Butcher
E-mail: elaine.butcher@dfait-macei.gc.ca

Agriculture and Agri-Food Canada
Market and Industry Services Branch
Sir John Carling Building
930 Carling Avenue
Ottawa, ON K1A 0C5Tel.: (613) 759-7744
Fax: (613) 759-7499
Contact: Jo-Anne Stewart
E-mail: stewartja@agr.gc.ca Internet:
http://www.agr.ca

Business Development Bank of Canada
5 Place Ville Marie, Suite 400
Montreal, QC H3B-2G2
Tel.: 1-888-463-6232
Fax: (514) 283-0617
Internet: http://www.bdc.ca

Export Development Corporation (EDC)
151 O'Connor St.
Ottawa, ON K1A 1K3Tel.: 1-888-332-3320 or
(613) 598-2500
Fax: (613) 237-2690
E-mail: export@edc-see.ca
Internet: http://www.edc.ca

Health Canada
International Affairs Directorate
Brooke Claxton Building, Room 814A
Postal Locator 0908A
Tunney's Pasture
Ottawa, ON K1A 0K9
Tel.: (613) 941-3136
Fax: (613) 952-7417
Internet: http://www.hc-sc.gc.ca

Industry Canada
Life Sciences Branch
PO Box 940, Station A
1801 Hollis Street
Halifax, NS B3J 2V9
Tel.: (902) 426-9958
Fax: (902) 426-2624
Contact: Mark Craig, Industry Development Officer, Bio-Industries
E-mail: craig.mark@ic.gc.ca
Internet: http://strategis.ic.gc.ca

Canadian Commercial Corporation (CCC)
50 O'Connor St., Suite 1100
Ottawa, ON K1A 0S6
Tel.: 1-800-748-8191 or (613) 996-0034
Fax: (613) 995-2121
Internet: http://www.ccc.ca

Israeli Government Contacts

Embassy of Israel
1005-50 O-Connor St.
Ottawa, ON K1P 6L2
Tel.: (613) 567-6450
Fax: (613) 237-8865
E-mail: embisrott@cyberus.ca
Consulate General of Israel: Toronto
180 Bloor Street West, Suite 700
Toronto, ON M5S 2V6
Tel.: (416) 640-8540
Fax: (416) 640-8546
Consulate General of Israel: Montreal
1155 René Lévesque West, Suite 2620
Montreal, QC H3B 4S5
Tel.: (514) 940-8515
Fax: (514) 940-8520

Israel National Biotechnology Steering Committee
PO Box 50216
Tel Aviv 61500, Israel
Tel.: (972-3) 511-8109
Fax: (972-3) 510-0622
E-mail: stel@moit.gov.il
Internet: http://www.irc.org.il/biotech/INBSC.htm
Note: A database of Israeli companies is available at http://www.irc.org.il/bio/classificationList.asp

Israel Patent and Trade Mark Office
PO Box 354
Jerusalem 91002, Israel
Tel.: (972-2) 670-8511
Fax: (972-2) 625-7928
Internet: http://www.justice.gov.il (Hebrew)

MATIMOP - Israeli Industry Center for Research and Development
PO Box 50364
Tel Aviv 61500, Israel
Tel.: (972-3) 517-0150
Fax: (972-3) 517-7655
E-mail: rdinfo@matimop.org.il
Internet: http://204.141.72.169/1/index.html

Ministry of Health
2 Ben-Tabai Street
Jerusalem 91010, Israel
Tel.: (972-2) 670-5705
Fax: (972-2) 678-1456
Internet: http://www.health.gov.il (Hebrew)
Pharmaceutical Division
PO Box 1176
Jerusalem 91010, Israel
Tel.: (972-2) 568-1216
Fax: (972-2) 572-5827
Internet: http://www.health.gov.il (Hebrew)

Ministry of Industry and Trade
Investment Promotions Centre
30 Agron Street
Jerusalem 94190, Israel
Tel.: (972-2) 622-0661
Fax: (972-2) 622-2412
E-mail: infoipc@moit.gov.il
Internet: http://www.moit.gov.il
Note: Government agency for foreign-based companies interested in investigating direct investment opportunities and joint ventures.
Office of the Chief Scientist4 Mevo Hamatmid
PO Box 2197
Jerusalem 91021, Israel
Tel.: (972-2) 677-0531
Fax: (972-2) 624-1064
E-mail: haizler@ocs.moit.gov.il
Internet: http://www.moit.gov.il

Ministry of Science, Culture and Sport
Government Offices, Building C
Hakirya Hamizrachit
Jerusalem 91490, Israel
Tel.: (972-2) 581-1220
Fax: (972-2) 581-1613
Internet: http://www.most.gov.il

Canada-Israel and Israeli Associations

Canada - Israel Industrial Research and Development Foundation
in Canada
875 Carling Avenue, Suite 430
Ottawa, ON K1S 5P1
Tel.: (613) 724-1284
Fax: (613) 724-1134
E-mail: ciirdf@cyberplus.ca
in Israel
PO Box 50364
Tel Aviv 61500, Israel
Tel.: (972-3) 511-8100
Fax: (972-3) 510-8758
E-mail: ciirdf@actcom.co.il

Federation of Israeli Chambers of Commerce
84 Hachashmonaim Street
Tel-Aviv 67011, Israel
Tel.: (972-3) 561-2444
Fax: (972-3) 561-2614
Internet: http://www.tlv-chamber.org.il

Israel Biotechnology Organization (IBO)
Chemical and Pharmaceutical Division
Industry House
29 Hamered Street
Tel Aviv 68125, Israel
Tel.: (972-3) 519-8875
Fax: (972-3) 519-8718
E-mail: chemical@industry.org.il
Internet: http://www.irc.org.il/biotech/Ibo.htm

Israel Export Institute
Healthcare and Biotechnology Department
Industry House
29 Hamered Street
PO Box 50084
Tel Aviv 68125, Israel
Tel.: (972-3) 514 2830
Fax: (972-3) 514-2902
Internet: http://www.export.gov.il

Israeli Medical Association
39 Shaul Hamelech Street
Tel Aviv, Israel
Tel.: (972-3) 696-9639
Fax: (972-3) 695-6103

Pharmacists Association
12 Lavontin Street
Tel-Aviv, Israel
Tel.: (972-3) 560-4541
Fax: (972-3) 560-5085

Standards Institution of Israel
42 Haim Lebanon Street
Tel-Aviv 69977, Israel
Tel.: (972-3) 646-5154
Fax: (972-3) 641-2762

Israeli Research Institutions

B.G. Negev Technologies & Applications Ltd.
Hashalom 1
PO Box 653
Beer Sheva 84105, Israel
Tel.: (972-7) 646-1908
Fax: (972-7) 627-6420
E-mail: orabgn@bgumail.bgu.ac.il
Internet: http://www.bgu.ac.il/bgu

Bar Ilan Research & Development Co. Ltd.
Bar Ilan University
Ramat Gan 52900, Israel
Tel.: (972-3) 531-8441
Fax: (972-3) 535-6088
E-mail: birnd@ashur.cc.biu.ac.il
Internet: http://www.biu.ac.il/birnd

Dimotech Ltd.
Technion City
Haifa 32000, Israel
Tel.: (972-4) 823-5829
Fax: (972-4) 823-2958
E-mail: lamiel@tx.technion.ac.il
Internet: http://www.technion.ac.il/technion/dimotech

Hadasit - Medical Research Services and Development Ltd.
PO Box 12000
Jerusalem 91120, Israel
Tel.: (972-2) 677-6095
Fax: (972-2) 643-7712
E-mail: arik@hadassah.org.il
Internet: http://www.hadassah.org.il

Institute for Applied Biosciences
Ben Gurion University of the Negev
PO Box 653
Beer Sheva 84105, Israel
Tel.: (972-7) 646-1963
Fax: (972-7) 647-2983
E-mail: arad@bgumail.bgu.ac.il
Internet: http://www.bgu.ac.il/iab

Life Sciences Research Israel Ltd.
PO Box 139
Nes Ziona 70451, Israel
Tel.: (972-8) 940-1110
Fax: (972-8) 940-1443
E-mail: lsri@netvision.net.il
Note: Owned by the Government of Israel; specializing in therapeutics, R&D services and contract research.

L. N. Innovative Technologies Ltd.
99 Hahistadrut St.
PO Box 25321
Haifa 31250, Israel
Tel.: (972-4) 842-2299
Fax: (972-4) 842-2550
E-mail: l-n-tech@inter.net.il

Migal - Galilee Technology Centre
PO Box 90000
Rosh Pina, 12100 Israel
Tel.: (972-6) 695-3505
Fax: (972-6) 694-4980
E-mail: arzi@migal.co.il
Note: Applied research institute specializing in biotechnology: medical, agriculture and environment.

RAMOT - Authority for Applied Research and Industrial Development Ltd.
Tel Aviv University
32 Haim Levanon Street
PO Box 39296
Ramat Aviv 61392, Israel
Tel.: (972-3) 640-8113
Fax: (972-3) 642-9865
E-mail: ramot@post.tau.ac.il
Internet: http://www.tau.ac.il/ramot

Yeda Research and Development Co. Ltd.
Weizmann Institute of Science
PO Box 95
Rehovot 76100, Israel
Tel.: (972-8) 947-0617
Fax: (972-8) 947-0739
E-mail: wyharel@wis.weizmann.ac.il
Internet: http://bioinformatics.
weizmann.ac.il/yeda/home.html

Yissum Research Development Company of the Hebrew University
46 Jabotinsky Street
PO Box 4279
Jerusalem 91042, Israel
Tel.: (972-2) 563-5149
Fax: (972-2) 566-0331
E-mail: moti@yissum.co.il
Internet: http://www.yissum.co.il

Israeli Sick Funds

Kupat Holim Clalit (General Sick Fund)
PO Box 16250
Tel Aviv 61162, Israel
Tel.: (972-3) 692-3433
Fax: (972-3) 691-0786

Maccabi Sick Fund
27 Hamered Street
Tel Aviv 68125, Israel
Tel.: (972-3) 514-3535
Fax: (972-3) 514-3640

Meuhedet Sick Fund
PO Box 16161
Tel Aviv 61161, Israel
Tel.: (972-3) 520-2323
Fax: (972-3) 524-2236

National Workers Sick Fund (Leumit)
PO Box 2209
Tel Aviv 61021, Israel
Tel.: (972-3) 697-0303
Fax: (972-3) 691-7219

Israeli Biotechnology Incubators

Bio Tech at HiTec
Har Hotzvim
PO Box 45010
Jerusalem 91450, Israel
Tel.: (972-2) 587-0710
Fax: (972-2) 581-2386
E-mail: biotec@netvision.net.il

Biosynergy Ltd.
Carmel Industrial Park
PO Box 2067
Tirat Carmel 39120, Israel
Tel.: (972-4) 858-0222
Fax: (972-4) 858-0220
E-mail: info@biosynergy.co.il

Eager Bio Ltd.
4 Habosem St.
Kiryat Hamada
PO Box 15212
Ashdod 22051, Israel
Tel.: (972-8) 853-6050
Fax: (972-8) 853-6052
E-mail: eager@hetk.net

Green Tech
Mofet B'yehuda Technology Incubator
PO Box 80
Kiryat Arba 90100, Israel
Tel.: (972-2) 996-3880
Fax: (972-2) 996-1571
E-mail: info@greentech.co.il
Internet: http://www.greentech.co.il

ICN -The Initiative Center of the Negev Ltd.
15 Yehoshua Hatsoref St.
PO Box 844
Beer Sheva 84106, Israel
Tel.: (972-7) 623-1212
Fax: (972-7) 623-1246
E-mail: icn@actcom.co.il
Internet: http://www.inc.co.il

ITEK -Incubator for Technological
Entrepreneurship Kiryat Weizmann
Building 13A Kiryat Weizmann Science Park
Ness Ziona 70400, Israel
Tel.: (972-8) 940-9086
Fax: (972-8) 940-8085
E-mail: itek@itek.co.il
Internet: http://www.itek.co.il

Medis El Ltd.
5 Kiryat Mada St.
PO Box 45031
Har Hotzvim Industrial Park
Jerusalem 91450, Israel
Tel.: (972-2) 587-0460
Fax: (972-2) 587-0454
E-mail: medis@medisel.co.il
Internet: http://www.medisel.com

Misgav Carmel Technology Incubator
Industrial Park Teradion
M.P. Misgav 20179, Israel
Tel.: (972-4) 999-1991
Fax: (972-4) 999-1901
E-mail: misgavte@actcom.co.il

Naiot Technological Center Ltd.
PO Box 732
Nazareth Ilit 17106, Israel
Tel.: (972-6) 656-4092
Fax: (972-6) 656-6735
E-mail: naiot@netvision.net.il
Internet: http://www.naiot.com

Rad Ramot, High Technologies Incubator Ltd.
Katzir 2a
Ramat Gan 52656, Israel
Tel.: (972-3) 635-0002
Fax: (972-3) 534-1650
E-mail: info@rad-ramot.co.il
Internet: http://www.rad-ramot.co.il

Israeli Platform Technology Companies

Advanced Biotech Ltd.
P.O.B. 3
Ariel 44837, Israel
Tel.: (972-3)906-6212
Fax: (972-3) 906-6162
E-mail: firer@research.yosh.ac.il

Allergene Ltd.
Katzir 2a,
Tel Hashomer Ramat Gan 52656, Israel
Tel.: (972-3) 534-2720
Fax: (972-3) 534-1650
E-mail: info@allergene.co.il
Internet: http://www.allergene.co.il

Biopixel Ltd.
Yoshua Hazoref 15, P.O.B. 844
Beer -Sheva 84106, Israel
Tel.: (972-7) 628-8198
Fax: (972-7) 628-8201
E-mail: biopixel@actcom.co.il
Internet: http://www.biopixel.com

BioSight Ltd.
Teradion Industrial Park,
P.O.B. 1366
Misgav 20179, Israel
Tel.: (972-4) 999-1996
Fax: (972-4) 999-1901
E-mail: biosight@mail.com

Biotechnology General Ltd.
Science Park, Kiryat Weizmann,
Ness-Ziona 76326, Israel
Tel.: (972-8) 938-1122
Fax: (972-8) 940-9041
E-mail: dovik@btgil.com
Internet: http://www.btgc.com

CBD Technology Ltd.
2 Pekeris St.,
Park Tamar, P.O.B 199,
Rehovot 76100, Israel
Tel.: (972-8) 931-9550
Fax: (972-8) 931-9515
E-mail: stancbd@netvision.net.il
Internet: http://www.cbdtech.com

Compugen Ltd.
72 Pinchas Rosen St.,
Tel Aviv 69512, Israel
Tel.: (972-3) 765-8585
Fax: (972-3) 765-8555
E-mail: carol@compugen.co.il
Internet: http://www.cgen.com

D-Pharm Ltd.
Kiryat Weizmann, Science Park Bldg.16,
P.O.Box 2313,
Rehovot 76123, Israel
Tel.: (972-8) 930-0794
Fax: (972-8) 930-0795
E-mail: info@dpharm.com
Internet: http://www.dpharm.com

Gamida Cell Ltd.
24 Kanfey Nesharim St.,
Givat Shaul,
Jerusalem 95464, Israel
Tel.: (972-2) 654-1702
Fax: (972-2) 651-4998
E-mail: avitreve@netvision.net.il
Internet: http://www.netvision.net.il/php/avitreve

GamidaGen Ltd.
3 Habosem St.
Ashdod 77610 , Israel
Tel.: (972-8) 853-6699
Fax: (972-8) 853-7733
E-mail: yakir@gamidagen.co.il
Internet: http://www.gamidagen.co.il

Glycodata Ltd.
3 Habosem St.,
Ashdod 77610, Israel
Tel.: (972-8) 856-920
Fax: (972-8) 856-3258
E-mail: yakir-y@netvision.net.il

IntelliGene Ltd.
8 Am Veolamo St.,
P.O.B. 35241, Givat Shaul,
Jerusalem 91351, Israel
Tel.: (972-2) 654-0333
Fax: (972-2) 654-0222
E-mail: benjy@intelligene.israel.net

M.D.R Tests Ltd.
P.O.B. 80
Kiryat Arba 90100, Israel
Tel.: (972-2) 996-3880
Fax: (972-2) 996-1571
E-mail: info@mofet.org.il
Internet: http://www.mofet.org.il

Mindset Ltd.
P.O.B. 45032,
Jerusalem 91450, Israel
Tel.: (972-2) 571-3579
Fax: (972-2) 571-3576
E-mail: dchaim@mindset.co.il

MultiQTL Ltd.
99 Hahistadrut st.,
Haifa, 31250, Israel
Tel.: (972-4) 842-3739
Fax: (972-4) 842-2550
E-mail: ariel@multiqtl.com
Internet: http://www.multiqtl.com

Novetide Ltd.
P.O.B. 10140,
Haifa Bay 26111, Israel
Tel.: (972-4) 846-9561
Fax: (972-4) 846-9320

Peptor Ltd.
Kiryat Weizmann,
Rehovot 76326, Israel
Tel.: (972-8) 938-7777
Fax: (972-8) 940-7737
E-mail: yoram@peptor.co.il
Internet: http://www.peptor.com

ProChon Biotech Ltd.
Bld. 12, Kiryat Weizmann, Science Park,
P.O.Box 1482
Rehovot 76114, Israel
Tel.: (972-8) 940-1570
Fax: (972-8) 940-1813
E-mail: aviezer@prochon.co.il

Stil Biotechnologies Ltd.
Katzir 2a
Ramat Gan 52656, Israel
Tel.: (972-3) 535-0968
Fax: (972-3) 534-1650
E-mail: info@stil.co.il
Internet: http://www.stil.co.il

Synergix Ltd.
Technology Park,
Malha, Building 1,
Jerusalem 91487, Israel
Tel.: (972-2) 648-0396
Fax: (972-2) 648-0399
E-mail: contact@synergic.co.il

Thixo
2 Hashaked St.,
Ness Ziyona 74104, Israel
Tel.: (972-8) 940-1340
Fax: (972-8) 940-2567
E-mail: eldar@bark-online.net

XTL Biopharmaceuticals Ltd.
Kiryat Weizmann,
Rehovot 76100, Israel
Tel.: (972-8) 940-5134
Fax: (972-8) 940-5017
E-mail: zachi@xtlbio.com
Internet: http://www.xtlbio.com

Israeli Therapeutics Companies

Adante Ltd.
Katzir 2a,
Ramat Gan 52656, Israel
Tel.: (972-3) 534-3748
Fax: (972-3) 534-1650
E-mail: adante@netvision.net.il
Internet: http://www.rad-ramot.co.il

Advanced Biotech Ltd.
P.O.B. 3
Ariel 44837, Israel
Tel.: (972-3) 906-6212
Fax: (972-3) 906-6162
E-mail: firer@research.yosh.ac.il

Allergene Ltd.
Katzir 2a, Tel Hashomer
Ramat Gan 52656, Israel
Tel.: (972-3) 534-2720
Fax: (972-3) 534-1650
E-mail: info@allergene.co.il
Internet: http://www.allergene.co.il

Advanced Nanoparticles
Har Hotzvim, P.O.B. 45010
Jerusalem 91450, Israel
Tel.: (972-2) 587-0710
Fax: (972-2) 581-2386
E-mail: biotech@netvision.net.il

ARP Biomed Inc.
Top Tower, 50 Dizengoff St.
Tel Aviv 64332, Israel
Tel.: (972-3) 620-9010
Fax: (972-3) 620-9011
E-mail: nava@columbinec.com

BioSight Ltd.
Teradion Industrial Park, P.O.B. 1366
Misgav 20179, Israel
Tel.: (972-4) 999-1996
Fax: (972-4) 999-1901
E-mail: biosight@mail.com

Biota Ltd.
P.O.B. 212
Nesher 36601, Israel
Tel.: (972-4) 830-8352
Fax: (972-4) 821-0531
E-mail: meir@algawish.com

Bioshaf Ltd.
Naiot, Technological Center, P.O.B. 732,
Nazareth Illit 17106, Israel
Tel.: (972-6) 656-7263
Fax: (972-6) 656-6735
E-mail: labs@netvision.net.il

Biotechnology General Ltd.
Science Park, Kiryat Weizmann
Ness -Ziona 76326, Israel
Tel.: (972-8) 938-1122
Fax: (972-8) 940-9041
E-mail: dovik@btgil.com
Internet: http://www.btgc.com

Collgard Biopharmaceuticals Ltd.
Textile House
2 Koifman Street
Tel-Aviv 68012, Israel
Tel.: (972-3) 516-0577
Fax: (972-3) 516-0576
E-mail: farbern@act.com
Internet: http://www.collgard.com

Cytolab Ltd.
Building 12, Kiryat Weizmann Science
P.O.B. 2416
Rehovot 76124, Israel
Tel.: (972-8) 940-3302/3336
Fax: (972-8) 940-3736
E-mail: cytolab@netvision.net.il
Internet: http://www.peprotech.com

D-Pharm Ltd.
Kiryat Weizmann, Science Park Bldg.16,
P.O.Box 2313
Rehovot 76123, Israel
Tel.: (972-8) 930-0794
Fax: (972-8) 930-0795
E-mail: info@dpharm.com
Internet: http://www.dpharm.com

Ester Neurosciences Ltd.
Textile House, 2 Koifman Street
Tel Aviv 68012, Israel
Tel.: (972-3) 516-0577
Fax: (972-3) 516-0576
E-mail: mvp@netvision.net.il

Excellent -Chelators Ltd.
Weizmann Institute Campus, P.O.B. 2439
Rehovot 76123, Israel
Tel.: (972-8) 936-5431
Fax: (972-8) 946-0484
E-mail: nurpamot@netvision.net.il

Galil Medical
P.O.B. 224
Yokneam 20692, Israel
Tel.: (972-4) 959-1080
Fax: (972-4) 959-1077
E-mail: ilo@galil-medical.co.il

FBIT Ltd.
2a Katzir St.
Ramat Gan 52656, Israel
Tel.: (972-3) 534-1694
Fax: (972-3) 534-1650
E-mail: info@fbit.co.il
Internet: http://www.fbit.co.il

Gamida Cell Ltd.
24 Kanfey Nesharim St.,
Givat Shaul
Jerusalem 95464, Israel
Tel.: (972-2) 654-1702
Fax: (972-2) 651-4998
E-mail: avitreve@netvision.net.il
Internet: http://www.netvision.net.il/php/avitreve

Glycodata Ltd.
3 Habosem St.
Ashdod 77610, Israel
Tel.: (972-8) 856-920
Fax: (972-8) 856-3258
E-mail: yakir-y@netvision.net.il

Insight Ltd.
P.O.B 2128, Rabin Science Park
Rehovot 76121, Israel
Tel.: (972-8) 946-3032
Fax: (972-8) 946-1042
E-mail: ntamari@insight.co.il

InterPharm Laboratories Ltd.
Science-Based Industrial Park, Kiryat Weizmann
Ness Ziona 76110, Israel
Tel.: (972-8) 938-2424
Fax: (972-8) 940-7566
E-mail: ipl.ziona.il_tlvŲ1@serono.com

Jexys
Har Hotzvim, P.O.B. 45010
Jerusalem 91450, Israel
Tel.: (972-2) 587-0710
Fax: (972-2) 581-2386
E-mail: biotec@netvision.net.il

Kamada Ltd.
Kiryat Weizmann
Rehovot 76327, Israel
Tel.: (972-8) 940-6472
Fax: (972-8) 940-6473
E-mail: kamadeal@kamada.com
Internet: http://www.kamada.com

Lavsys Ltd.
Ramot, P.O.B. 39296
Tel Aviv 61392, Israel
Tel.: (972-3) 640-9832
Fax: (972-3) 642-9865
E-mail: ramot@ccsg.tau.ac.il

Medis El Ltd.
Shabazi 14, P.O.B. 132
Yahud 56101, Israel
Tel.: (972-3) 632-2130
Fax: (972-3) 632-1671
E-mail: medis@medisel.co.il
Internet: http://www.medisel.com

Meditor Pharmaceuticals Ltd.
10 Menahem Plaut St.
Tamar Park
Rehovot 76123, Israel
Tel.: (972-8) 938-0903
Fax: (972-8) 931-6360
E-mail: tdov@inter.net.il

Merav Biological Industries Ltd.
P.O.B. 13666, Terdion Industrial Park
Misgav 20179, Israel
Tel.: (972-4) 999-1997
Fax: (972-4) 999-1901
E-mail: meravbio@netvision.net.il

Mindset Ltd.
P.O.B. 45032
Jerusalem 91450, Israel
Tel.: (972-2) 571-3579
Fax: (972-2) 571-3576
E-mail: dchaim@mindset.co.il

OMRI Laboratories Ltd.
Weizmann Scientific Park
Rehovot. P. O. Box 619
Rehovot 76106, Israel
Tel.: (972-8) 930-0227
Fax: (972-8) 930-1219
E-mail: moshe@omrix.co.il
Internet: http://www.arrowecology.com

Partec Ltd.
216 Jaffa Rd.
Jerusalem, Israel
Tel.: (972-2) 537-4997
Fax: (972-2) 537-5098
E-mail: ira@partec_ltd.com
Internet: http://www.partec_ltd.com

Peptor Ltd.
Kiryat Weizmann
Rehovot 76326, Israel
Tel.: (972-8) 938-7777
Fax: (972-8) 940-7737
E-mail: yoram@peptor.co.il
Internet: http://www.peptor.com

Pharmos Ltd.
Kiryat Weizmann
Rehovot 76326, Israel
Tel.: (972-8) 940-9679
Fax: (972-8) 940-9686
E- Mail: pars@pharmos.com
Internet: http://www.pharmoscorp.com

Polyheal Ltd.
99 Hahistadrut Ave. P.O.B. 25321
Haifa 31253, Israel
Tel.: (972-8) 490 594
Fax: (972-4) 849-0595
E-mail: m-zeevi@inter.net.il

ProChon Biotech Ltd.
Bld. 12, Kiryat Weizmann, Science Park
P.O.Box 1482
Rehovot 76114, Israel
Tel.: (972-8) 940-1570
Fax: (972-8) 940-1813
E-mail: aviezer@prochon.co.il

Proneuron Biotechnologies ( Israel) Ltd.
P.O.Box 277 Ness -Ziona 74101
Tel.: (972-8) 940-9550
Fax: (972-8) 940-9560
E-mail: info@proneuron.com
Internet: http://www.proneuron.com

Rimonest Ltd.
Technion Entrepreneurial Center, Scientific Park
Nesher 36601, Israel
Tel.: (972-4) 830-8359
Fax: (972-4) 821-0531
E-mail: rimonest@netvision.net.il

S. I. Biotechnology
27 Emeck Haberacah St.
Tel Aviv 67456, Israel
Tel.: (972-3) 695-9717
Fax: (972-3) 695-4711
E-mail: sibiotec@inter.net.il

Sigyn Pharmaceuticals
Har Hotzvim, P.O.B. 45010
Jerusalem 91450, Israel
Tel.: (972-2) 587-0710
Fax: (972-2) 581-2386
E-mail: biotec@netvision.net.il

Stil Biotechnologies Ltd.
Katzir 2a
Ramat Gan 52656, Israel
Tel.: (972-3) 535-0968
Fax: (972-3) 534-1650
E-mail: info@stil.co.il
Internet: http://www.stil.co.il

Synergix Ltd.
Technology Park, Malha, Building 1
Jerusalem 91487, Israel
Tel.: (972-2) 648-0396
Fax: (972-2) 648-0399
E-mail: contact@synergic.co.il

Tamarkin Pharmaceutical Innovation Ltd.
Address: P.O.B. 2463
Rehovot 76123, Israel
Tel.: (972-8) 938-0903
Fax: (972-8) 931-6360
E-mail: tdov@inter.net.il

Teva Pharmaceutical Industries
P.O.B. 3190
Petach Tikva 49131, Israel
Tel.: (972-3) 926-7267
Fax: (972-3) 923-4050
E-mail: gil.barzilay@teva.co.il
Internet: http://www.tevapharm.com

ViroGene Ltd.
Har Hotzvim, P.O.B. 45010
Jerusalem 91450, Israel
Tel.: (972-2) 587-0710
Fax: (972-2) 581-2386
E-mail: biotec@netvision.net.il

XTL Biopharmaceuticals Ltd.
Kiryat Weizmann
Rehovot 76100, Israel
Tel.: (972-8) 940-5134
Fax: (972-8) 940-5017
E-mail: zachi@xtlbio.com
Internet: http://www.xtlbio.com

Israeli Bioinformatic Companies

Compugen Ltd.
72 Pinchas Rosen St.
Tel Aviv 69512, Israel
Tel.: (972-3) 765-8585
Fax: (972-3) 765-8555
E-mail: carol@compugen.co.il
Internet: http://www.cgen.com

Green Care Laboratories Ltd.
Derech Haharoshet 10
P.O.B. 720
Kiryat Gat 82000, Israel
Tel.: (972-7) 660-2888
Fax: (972-7) 660-2777
E-mail: enrad@multinet.net.il

MultiQTL Ltd.
99 Hahistadrut st.,
Haifa 31250, Israel
Tel.: (972-4) 842-3739
Fax: (972-4) 842-2550
E-mail: ariel@multiqtl.com
Intenet: http://www.multiqtl.com

Glycodata Ltd.
3 Habosem St.
Ashdod 77610, Israel
Tel.: (972-8) 856-920
Fax: (972-8) 856-3258
E-mail: yakir-y@netvision.net.il

Israeli Contract Research and Manufacturing Companies

Alomone Labs
HaMarpeh 5, P.O.B. 4287
Jerusalem 91042, Israel
Tel.: (972-2) 587-1102
Fax: (972-2) 587-1101
E-mail: alomone@netvision.net.il
Internet: http://www.alomone.com

Bactochem Ltd.
2 Hacharash St.
Ness Ziona, Israel
Tel.: (972-8) 940-1442
Fax: (972-8) 940-1439
E-mail: pinnir@netvision.net.il

Fermentek Ltd.
P.O.B. 47120 Atarot
Jerusalem 97800, Israel
Tel.: (972-2) 585-3953
Fax: (972-2) 585-3943
E-mail: fermntec@inter.net.il
Internet: http://www.fermentek.co.il

Galil Agribiotech Ltd.
Teradion Industrial Park
Misgav 20179, Israel
Tel.: (972-4) 999-1222
Fax: (972-4) 999-1248
E-mail: galillab@netvision.net.il
Internet: http://www.ggtweb.com

Harlan BioTech Israel Ltd.
Kiryat Weizmann, Building 13B
Rehovot 76326, Israel
Tel.: (972-8) 940-9451
Fax: (972-8) 940-9452
E- Mail: hbi@netvision.net.il
Internet: http://www.netspell.com/harlan

IMI (Tami) Institute Research and Development Ltd.
P.O.B. 10140
Haifa Bay 26111, Israel
Tel.: (972-4) 846-9546
Fax: (972-4) 845-0078
E-mail: eddy@tami-imi.co.il
Internet: http://www.tami-imi.com

Kamada Ltd.
Kiryat Weizmann
Rehovot 76327, Israel
Tel.: (972-8) 940-6472
Fax: (972-8) 940-6473
E-mail: kamadeal@kamada.com
Internet: http://www.kamada.com

Migal - Galilee Technological Center
P.O.B 90000
Rosh- Pina 12100, Israel
Tel.: (972-6) 695-3511
Fax: (972-6) 694-4980
E-mail: arzi@migal.org.il
Internet: http://www.migal.co.il

Novetide Ltd.
P.O.B. 10140
Haifa Bay 26111, Israel
Tel.: (972-4) 846-9561
Fax: (972-4) 846-9320

Savyon Diagnostics Ltd.
Habosem 3
Ashdod 77610, Israel
Tel.: (972-8) 856-2920
Fax: (972-8) 856-3258
E-mail: savyon_d@netvision.net.il

Zohar Dalia - (Biotech Dept.)
Kibbutz Dalia 19239, Israel
Tel.: (972-4) 989-7234
Fax: (972-4) 989-7200
E-mail: zohar@zohar.co.il
Internet: http://www.zohar.co.il

Israeli Diagnostic Companies

Advanced Monitoring Systems -AMS
P.O.B.286
Yokneham 20692, Israel
Tel.: (972-6) 959-1984
Fax: (972-6) 959-1989
E-mail: mishael@metroptic.com
Internet: http://www.ofek.org.il/ams

Advanced Nanoparticles
Har Hotzvim, P.O.B. 45010
Jerusalem 91450, Israel
Tel.: (972-2) 587-0710
Fax: (972-2) 581-2386
E-mail: biotech@netvision.net.il

ASI -Applied Spectral Imaging Ltd.
Industrial Park Ramat Gavriel,
P.O.B. 101
Migdal Ha'emek 10551, Israel
Tel.: (972-6) 654-7567
Fax: (972-6) 654-7507
E-mail: asi-ltd@spectral-imaging .com
Internet: http://www.spectral-imaging.com

Biogal - Galed Labs.
Kibbutz Galed 19240 M.P.
Megiddo, Israel
Tel.: (972-4) 989-8605
Fax: (972-4) 989-8690
E-mail: biogal@galed.org.il
Internet: http://www.biogal.co.il

Bio Magnetics Ltd.
P.O.B. 3
Ariel 44837, Israel
Tel.: (972-3) 936-5341
Fax: (972-3) 936-6873
E-mail: bmagnet@netvision.net.il

Biopixel Ltd.
Yoshua Hazoref 15, P.O.B. 844
Beer -Sheva 84106, Israel
Tel.: (972-7) 628-8198
Fax: (972-7) 628-8201
E-mail: biopixel@actcom.co.il
Internet: http://www.biopixel.com

BioPreventive Ltd.
P.O.B. 732
Nazareth Illit 17106, Israel
Tel.: (972-6) 608-2663
Fax: (972-6) 608-0896
E-mail: ranny-y@netvision.net.il
Internet: http://www.biopreventive.com

Bioshaf Ltd.
Naiot, Technological Center, P.O.B. 732
Nazareth Illit 17106, Israel
Tel.: (972-6) 656-7263
Fax: (972-6) 656-6735
E-mail: labs@netvision.net.il

BioSight Ltd.
Teradion Industrial Park, P.O.B. 1366
Misgav 20179, Israel
Tel.: (972-4) 999-1996
Fax: (972-4) 999-1901
E-mail: biosight@mail.com

Cellstain Technologies Ltd.
Kiryat Weizmann, Science Park, Blg. 13A
Ness Ziona 70400, Israel
Tel.: (972-8) 930-1157
Fax: (972-8) 940-8085
E-mail: cellstai@netvision.net.il

Common Sense Ltd.
P.O.B. 732
Nazareth Illit 17106, Israel
Tel.: (972-6) 646-0178
Fax: (972-6) 656-6735
E-mail: comsens@inter.net.il

FBIT Ltd.
2a Katzir St.
Ramat Gan 52656, Israel
Tel.: (972-3) 534-1694
Fax: (972-3) 534-1650
E-mail: info@fbit.co.il
Internet: http://www.fbit.co.il

GamidaGen Ltd.
3 Habosem St.
Ashdod 77610, Israel
Tel.: (972-8) 853-6699
Fax: (972-8) 853-7733
E-mail: yakir@gamidagen.co.il
Internet: http://www.gamidagen.co.il

Glycodata Ltd.
3 Habosem St.
Ashdod 77610, Israel
Tel.: (972-8) 856-920
Fax: (972-8) 856-3258
E-mail: yakir-y@netvision.net.il

InnoScent Ltd.
Katzir 2a
Ramat Gan 52656, Israel
Tel.: (972-3) 534-2108
Fax: (972-3) 534-1650
E-mail: scent@netvision.net.il
Internet: http://www.rad-ramot.co.il

Insight Ltd.
P.O.B 2128, Rabin Science Park
Rehovot 76121, Israel
Tel.: (972-8) 946-3032
Fax: (972-8) 946-1042
E-mail: ntamari@insight.co.il

IntelliGene Ltd.
8 Am Veolamo St., P.O.B. 35241, Givat Shaul
Jerusalem 91351, Israel
Tel.: (972-2) 654-0333
Fax: (972-2) 654-0222
E-mail: benjy@intelligene.israel.net

M.D.R Tests Ltd.
P.O.B. 80
Kiryat Arba 90100, Israel
Tel.: (972-2) 996-3880
Fax: (972-2) 996-1571
E-mail: info@mofet.org.il
Internet: http://www.mofet.org.il

Savyon Diagnostics Ltd.
Habosem 3
Ashdod 77610, Israel
Tel.: (972-8) 856-2920
Fax: (972-8) 856-3258
E-mail: savyon_d@netvision.net.il

Medis El Ltd.
Shabazi 14, P.O.B. 132, Yahud 56101, Israel
Tel.: (972-3) 632-2130
Fax: (972-3) 632-1671
E-mail: medis@medisel.co.il
Internet: http://www.medisel.com

Mindsense Biosystems Ltd.
Hamada 12, Rabin Park, Tamar Building
Rehovot 76703, Israel
Tel.: (972-8) 931-6664
Fax: (972-8) 931-6665
E-mail: info@Mindsense.com
Internet: http://www.mindsense.com

Neurogenic Ltd.
P.O.B 29866
Tel-Aviv 61298, Israel
Tel.: (972-3) 510-1992
Fax: (972-3) 510-0049
E-mail: wcmyosi@inter.net.il

Novamed Ltd.
28 Pierre Koenig St. P.O.B 53231
Jerusalem 91531, Israel
Tel.: (972-2) 678-1861
Fax: (972-2) 678-1852
E Mail: novamed@netvision.net.il

Orgenics Ltd.
P.O.B 360
Yavne 70650, Israel
Tel.: (972-8) 942-9201
Fax: (972-8) 943-8758
E-mail: info@orgenics.com
Internet: http://www.orgenics.com

Partec Ltd.
216 Jaffa Rd.
Jerusalem, Israel
Tel.: (972-2) 537-4997
Fax: (972-2) 537-5098
E-mail: ira@partec_ltd.com
Internet: http://www.partec_ltd.com

Zer Hitech (1976) Ltd.
Shatner Center 3, Givat Shaul B, Jerusalem
95461, Israel
Tel.: (972-2) 652-2462
Fax: (972-2) 651-2898
E-mail: contactus@zerhitech.com

Canadian Biotechnology Associations

Alberta Biotechnology Association
1150, 10180 - 101 Street
Edmonton, AB T5J 3S7
Tel.: (780) 425-3815
Fax: (780) 423-3893
Contact: Myka Osinchuk
E-mail: myka@bioalberta.com
Internet: http://www.bioalberta.com

BioAtlantech
PO Box 636, Station A
Fredericton, NB E3B 5A6
Tel.: (506) 444-2444
Fax: (506) 444-5662
Contact: John Argall, Executive Director
E-mail: jargall@fundy.net
Internet: http://www.bioatlantech.nb.ca

BioEast
c/o Seabright Corporation Ltd.
Memorial University of Newfoundland
Spencer Hall
220 Prince Philip Drive
St. John's, NF A1C 5S7
Tel.: (709) 737-4527
Fax: (709) 737-4029
Contact: David King, President
Internet: http://www.mun.ca/seabright/bioeast

BIONova
c/o Innovacorp
101 Research Dr.
PO Box 790
Dartmouth, NS B2Y 3Z7
Tel.: (902) 424-8670
Fax: (902) 424-4679
Contact: Bill Mills, Executive Director
E-mail: bmills@innovacorp.ns.ca

BIOTECanada
130 Albert St., Suite 420
Ottawa, ON K1P 5G2
Tel.: (613) 563-8849
Fax: (613) 563-8850
E-mail: info@biotech.ca
Internet: http://www.biotech.ca

British Columbia Biotechnology Alliance
3250 East Mall, Suite 220
Vancouver, BC V6T 1W5
Tel.: (604) 221-3026
Fax: (604) 221-3027
Contact: Theresa McCurry, Executive Director
Internet: http://www.biotech.bc.ca

Canada's Research-Based Pharmaceutical Companies
302-1111 Prince of Wales Drive
Ottawa, ON K2C 3T2
Tel.: (613) 727-1380
Fax: (613) 727-1407
Internet: http://www.canadapharma.org

Canadian Drug Manufacturers Association
4120 Young St., Suite 606
North York, ON M2P 2B8
Tel.: (416) 223-2333
Fax: (416) 223-2425
Internet: http://www.cdma-acfpp.org

Canadian Medical Association
1867 Alta Vista Dr.
Ottawa, ON K1G 3Y6
Tel.: (613) 731-9331
Internet: http://www.cma.ca

Canadian Wholesale Drug Association
(CDWA)
5255 Yonge St., Suite 505
Toronto, ON M2N 6P4
Tel.: (416) 222-3922
Fax: (416) 222-8960
Internet: http://www.cwda.com

Non-Prescription Drug Manufacturers Association of Canada
1111 Prince of Wales Drive, Suite 406
Ottawa, ON K2C 3T2
Tel.: (613) 723-0777
Fax: (613) 723-0779
E-mail: ndmac@ndmac.ca
Internet: http://www.ndmac.org

Quebec Bio-Industries Association
801, route 344
PO Box 3158
L'Assomption, QC J5W 4M9
Tel.: (450) 589-4628
Fax: (450) 589-4866
E-mail: info@aqb.qc.ca
Internet: http://www.aqb.qc.ca

Toronto Biotechnology Initiative
64 Old Burnhamthorpe Rd
Etobicoke, ON M9C 3J5
Tel.: (416) 626-1835
Fax: (416) 626-1423
Contact: David Harper
E-mail: davidh@yorkmedical.on.ca

BIBLIOGRAPHY

Chemical Business Newsbase. "Pharmaceuticals in Israel: Pharmaceutical Industry Expands Abroad," December 1999.

---. "Israeli Patent Row," January 1998.

Department of Foreign Affairs and International Trade. "Doing Business in Israel," March 1999. Available online at: http://www.infoexport.gc.ca.

---. "The Pharmaceutical and Vitamin Market in Israel," June 1998. Available online at: http://www.infoexport.gc.ca.

Drug Store News. "Teva signs definitive Agreement to Acquire Novopharm Ltd.," February 2000.

Dun & Bradstreet. "Exporters' Encyclopaedia - Israel," 1999.

Espicom Business Intelligence. "Medistat - Country Profiles: Israel", October 1999.

Economist Intelligence Unit Limited. "Science and Technology - Biomedical Research in Israel: Overview," Health Care International, March 1998.

Fishman, Dr. Rachelle H.B. "Innovations in Medical Technology," Focus on Israel, August 1999. Available online at: http://www.israel-mfa.gov.il/mfa/go.asp?MFAH0g7y0.

Jewish Week, "Major Push for Biotech Partnerships: U.S. - Israeli Deals in Medical Research, Pharmaceuticals Focus of New Initiative," July 1998.

Marketletter. "Israel Adopts Dutch Drug Import Pricing System," February 1998.

---. "Israel: Revised Patent Law Passes First Reading," November 1997.

---. "Israel Patent Move "Regrettable," March 1998.

---. "Israeli Cabinet Accepts Drug Price Cut Proposals," February 1998.

---. "Israeli Drug Industry and Market Forecasts," March 1997.

---. "Israeli Government Accepts Plan for Parallel Imports," September 1997.

---. "Israeli GSF Gets Tough with Drugmakers," March 1998.

---. "Israel's Drug Patent Laws Slammed," September 1997.

---. "Pharmacists/Importer Appeal Israeli Drug Prices," July 1998.

---. "Potential for Growth in Israel's OTC Market," November 1996.

Ministry of Industry and Trade, Investment Promotion Center. "Biotechnology in Israel: A Guide to Israel's Biotechnology Industry," 1999.

Price Waterhouse. "Emerging Opportunities for Canadian Businesses in Israel," February 1997.

Oxford Analytica Brief. "Israel: Pharmaceutical Patents," February 1998.

Scrip Publications, "Israel/EU in GLP Agreement," October 1999.

Sher, Hanan. "Biotech: Down, But Far from Out," Jerusalem Report, February 1999.

Siegel, Judy. "Foreign Drug Companies Set up Local Lobby," Jerusalem Post, February 1999.

---. "New Regulations Make Drug Market More Competitive," Jerusalem Post, May 2000.

United States Department of Commerce. "Country Commercial Guides - Israel: Trade Regulations and Standards," 1997.

---. "Country Commercial Guides - Marketing U.S. Products and Services," 1997.

OTHER REFERENCE MATERIALS

Useful Internet Sites

BioResearch Online: http://www.bioresearchonline.com

Canada Business Service Centres: http://www.cbsc.org

Canadian Commercial Corporation: http://www.ccc.ca

Canadian Exporters Catalogue: http://www.worldexport.com

Canada-Israel Industrial R&D Foundation: http://www.ciirdf.ca

Department of Foreign Affairs and International Trade: http://www.dfait-maeci.gc.ca

European Agency for the Evaluation Of Medicinal Products: http://www.eudra.org/emea.html

European Congress on Biotechnology: http://www.ecb9.be/Welcome.html

ExportSource: http://exportsource.gc.ca

Health Canada: http://www.hc-sc.gc.ca

Industry Canada/Strategis: http://strategis.ic.gc.ca

InfoExport: http://www.infoexport.gc.ca

Israel Biotechnology Company Database: http://www.irc.org.il/bio/classificationList.asp

Israel Biotechnology Organization: http://www.irc.org.il/biotech/Ibo.htm

Israel Government Gateway: http://www.info.gov.il/eng/mainpage.htm

Israel Investment Promotion Centre: http://www.irc.org.il/biotech/incentives

Organization for Economic Co-operation And Development: BioTrack Online: http://www.oecd.org/ehs/icgb/index.htm

Pharmaceutical Information Network: http://pharminfo.com/phrmlink.html

Pharmweb: http://www.pharmweb.net

1 All monetary amounts are expressed in Canadian dollars, unless otherwise indicated. The conversion rate to Canadian dollars is based on IDD Information Services, Tradeline, April 2000.

2 For contact information regarding key organizations mentioned in this report, see Key Contacts and Support Services at the end of the report.